Immunosuppressive regimens in lung transplant recipients

Sangeeta M. Bhorade*, Jaime Villanueva, Ashby Jordan, Edward R. Garrity

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

A lung transplant is usually the last resort treatment for lung failure. Since the introduction of cyclosporine A, success rates after solid organ transplantation began to rise, following an incremental curve over the last decade, in which further development of biological agents and newer immunosuppressive agents has continued to improve outcomes after transplantation. Pharmacokinetic and pharmacodynamic properties, as well as efficacy and safety data from clinical trials with immunosuppressive agents and biological agents currently available, are reviewed here.

Original languageEnglish (US)
Pages (from-to)1003-1012
Number of pages10
JournalDrugs of Today
Volume40
Issue number12
DOIs
StatePublished - Dec 1 2004

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Immunosuppressive regimens in lung transplant recipients'. Together they form a unique fingerprint.

Cite this